At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 95 target
Drug / intervention
Denosumabdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Denosumab and Male Infertility: a Randomized Controlled Double-blinded Intervention Study
In Brief
A Phase 2 clinical trial evaluating Denosumab for Infertility, Male. Completed, enrolled 95 participants across 1 site.
Detailed Summary
To determine the significance of systemic RANKL inhibition for male reproduction, conducting a clinical controlled randomized double blinded intervention study on infertile men, to investigating whether Denosumab (Prolia) can increase semen quality and to investigate what subgroup of infertile men that might benefit from treatment.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsInfertility, Male
CountriesDenmark
Collaborators--
Timeline
Phase 2CompletedFinished
2017201820192020202120222023202420252026
Enrollment StartJan 2017
First PostedJan 2017
Primary CompletionJan 2021
Study CompletionMay 2023
TodayJul 2026
First PostedJan 24, 2017
Enrollment StartJan 1, 2017
Primary CompletionJan 1, 2021
Study CompletionMay 1, 2023
TodayJul 2, 2026
Enrollment to primary: 4 yearsPosted 9.4 years ago
Interventions
Denosumabdrug
NaCl 0.9% injection is used as placebo